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Abstract
Healthcare companies must submit pharmaceuti-
cal drugs or medical devices to regulatory bodies
before marketing new technology. Regulatory
bodies frequently require transparent and inter-
pretable computational modelling to justify a new
healthcare technology, but researchers may have
several competing models for a biological sys-
tem and too little data to discriminate between
the models. In design of experiments for model
discrimination, the goal is to design maximally
informative physical experiments in order to dis-
criminate between rival predictive models. Prior
work has focused either on analytical approaches,
which cannot manage all functions, or on data-
driven approaches, which may have computa-
tional difficulties or lack interpretable marginal
predictive distributions. We develop a method-
ology introducing Gaussian process surrogates
in lieu of the original mechanistic models. We
thereby extend existing design and model discrim-
ination methods developed for analytical models
to cases of non-analytical models in a computa-
tionally efficient manner.
1. Introduction
A patient’s health and safety is an important concern, and
healthcare is a heavily regulated industry. In the USA and
the EU, private and public regulatory bodies exist on fed-
eral/union and state levels (Field, 2008; Hervey, 2010).
Healthcare companies applying to market a new drug or
medical device must submit extensive technical information
to the regulatory bodies. In the USA and the EU, the Food
& Drug Administration (FDA) and European Medicines
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Agency (EMA) handle these applications, respectively. The
FDA require that the technical information contains e.g. the
chemical composition of the drug, how the drug affects the
human body (pharmacodynamics), how the body affects the
drug (pharmacokinetics), and methods for drug manufac-
turing, packaging and quality control (U.S. Food & Drug
Administration, 2018). Likewise, applying to market a new
medical device requires submitting extensive technical in-
formation. A medical device can be any appliance, software
or material used for non-pharmacological diagnosis, mon-
itoring or treatment of a disease or condition (European
Union, 2017). An important part of proving the efficacy and
safety of a new drug or medical device is showing that its
effects on the patient can be predicted and interpreted, e.g.
via mathematical and computational models.
These transparency and interpretability requirements, com-
bined with limited amounts of available experimental data,
make models learnt solely from observed data unsuitable for
proving the efficacy and safety of a new drug or medical de-
vice to the regulatory bodies. Hence researchers use explicit
parametric models. For drugs, the pharmacokinetics (how
the human body affects the drug) is often modelled using
systems of ordinary differential equations. These models
elucidate how the drug is absorbed and distributed through
the body (e.g. brain, kidneys and liver) under different dos-
ing profiles and methods of drug administration (e.g. orally
or intravenously) (see Figure 1). The EMA pharmacokinetic
model guidelines state that regulatory submissions should
include detailed descriptions of the models, i.e. justification
of model assumptions, parameters and their biochemical
plausibility, as well as parameter sensitivity analyses (Euro-
pean Medicines Agency, 2011, p. 16; 2016, p. 3).
A key problem is to identify a mathematical model that
usefully explains and predicts the behaviour of the phar-
macokinetic process (Heller et al., 2018). Researchers will
often have several models (i.e. hypotheses) about an underly-
ing mechanism of the process, but insufficient experimental
data to discriminate between the models (Heller et al., 2018).
Additional experiments are generally expensive and time-
consuming. Pharmacokinetic experiments typically take
8–24 hours for mice and rats, and 12–100 hours for simians
and humans (Ogungbenro & Aarons, 2008; Tuntland et al.,
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Figure 1. Different aspects of pharmacokinetic models. (Top left) simple pharmacokinetic model with four compartments: digestive
system, liver, bloodstream and other tissue. The drug can enter as tablets into the digestive system or as an injection into the bloodstream,
and leave the system by being excreted as waste. (Bottom left) the effect on drug concentration in a patient from two different dosing
profiles: (i) half the dose twice per day, or (ii) the full dose once per day. (Centre) two different methods of drug administration: orally in
the form of tablets, or intravenously as an injection, and (Right) their different effects: an injection has a quicker effect than tablets.
2014). It is key to design experiments yielding maximally
informative outcomes with respect to model discrimination.
Contribution We tackle limitations in existing analyti-
cal and data-driven approaches to design of experiments
for model discrimination by bridging the gap between the
classical analytical methods and the Monte Carlo-based
approaches. These limitations include the classical analyt-
ical methods’ difficulty to manage non-analytical model
functions, and the computational cost for the data-driven
approaches. To this end, we develop a novel method of
replacing the original parametric models with probabilis-
tic, non-parametric Gaussian process (GP) surrogates learnt
from model evaluations. The GP surrogates are flexible
regression tools that allow us to extend classical analytical
results to non-analytical models in a computationally effi-
cient manner, while providing us with confidence bounds
on the model predictions.
The method described in this paper has been implemented
in a python software package, GPdoemd (2018), publicly
available via GitHub under an MIT License.
2. Model Discrimination
Model discrimination aims to discard inaccurate models,
i.e., hypotheses that are not supported by the data. Assume
M > 1 modelsMi are given, with corresponding model
functions f i(x,θi). The model is a hypothesis and col-
lection of assumptions about a biological system, e.g. the
pharmacokinetic model in the top left of Figure 1, and the
function is the model’s mathematical formulation that can
be used for predictions, e.g. the drug concentrations on the
right in Figure 1. Each model function f i takes as inputs
the design variables x ∈ X ⊂ Rd and model parameters
θi ∈ Θi ⊂ RDi . The design variables x, e.g. drug admin-
istration and dosing profile, specify a physical experiment
that can be run on the system described by the models, with
X defining the operating system boundaries. The classical
setting allows tuning of the model parameters θi to fit the
model to data. The system has E ≥ 1 target dimensions, i.e.
f i : Rd+Di → RE . We denote the function for each target
dimension e as fi,(e). This notation distinguishes between
the eth target dimension f(e) of a model function f , and
model Mi’s function f i. Table A in the supplementary
material summarises the notation used.
We start with an initial set of N0 experimental measure-
ments yn = f true(xn) + n, n = 1, . . . , N0. A common
assumption in pharmacokinetics is that the measurement
noise term n is i.i.d. zero-mean Gaussian distributed with
covariance Σexp (Steimer et al., 1984; Ette & Williams,
2004; Tsimring, 2014). Skew in the data distribution can
be handled, e.g. through log-transformation. The experi-
mental data set is denoted Dexp = {yj ,xj}. The initial
N0 experimental data points are insufficient to discriminate
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between the models, i.e. ∀ i : p(Mi | Dexp) ≈ 1/M . We
are agnostic to the available experimental data, and wish to
incorporate all of it in the model discrimination.
2.1. Classical Analytical Approach
Methods for tackling the design of experiments for dis-
criminating simple, analytical models have been around
for over 50 years. Box & Hill (1967) study the ex-
pected change E[∆S] = E[SN+1] − SN in Shannon
entropy SN =
∑
i pii,N log pii,N from making an addi-
tional experimental observation, where the posterior model
probability pii,N+1 = p(y|Mi)pii,N/p(y) and p(y) =∑
i p(y|Mi)pii,N . Box & Hill (1967) develop a design
criterion DBH by maximising the upper bound on E[∆S].
The expression for DBH can be found in the supplementary
material. MacKay (1992a;b) derives a similar expression.
Box & Hill (1967) choose the next experiment by finding
x∗ = arg maxxDBH. Design of experiments continues
until there exists a model probability piN,i ≈ 1.
Buzzi-Ferraris et al. (1990) propose a new design criterion
DBF (see the supplementary material) from a frequentist
point-of-view. They suggest using a χ2 test with NE −Di
degrees of freedom for the model discrimination. The null
hypothesis for each model is that the model has generated
the experimental data. Design of experiments continues
until only one model passes the χ2 test. Models are not
ranked against each other since Buzzi-Ferraris et al. (1990)
argue this simply leads to the least inaccurate model being
selected. The χ2 procedure is more robust against—but not
immune to—favouring the least inaccurate model.
Michalik et al. (2010) proceed from the Akaike information
criterion (AIC) as the model discrimination criterion to de-
rive a design criterion DAW from the Akaike weights wi.
The expression for DAW can be found in the supplementary
material. Design of experiments continues until there exists
an Akaike weight wi ≈ 1. Box & Hill (1967) and Michalik
et al. (2010) implicitly favour the least inaccurate model.
In order to account for the uncertainty in the model pa-
rameters θ, the classical analytical approach (Prasad &
Someswara Rao, 1977; Buzzi-Ferraris et al., 1984) is to
approximate the model parameters as being Gaussian dis-
tributed N (θˆ,Σθ) around the best-fit parameter values θˆ.
The covariance Σθ is given by a first-order approximation
Σ−1θ =
N∑
n=1
∇θfni >Σ−1exp∇θfni , (1)
where fni = f i(xn,θ), xn ∈ Dexp, and the gradient
∇θf i = ∂f i(x,θi)/∂θi|θi=θˆi . The predictive distri-
bution with θ approximately marginalised out becomes
p(f i |x,Dexp) = N (f i(x, θˆ), Σ˘i(x)), where the covari-
ance is Σ˘i(x) = ∇θf iΣθ∇θf>i .
Limitations Most model functions for healthcare applica-
tions such as pharmacokinetics or medical devices are not
analytical. They are often, from a practical point-of-view,
complex black boxes of legacy code, e.g. large systems of
ordinary or partial differential equations. We can evaluate
the model function f i, but the gradients∇θf i are not read-
ily available. Specialist software can retrieve the gradients
∇θf i from systems of ordinary or partial differential equa-
tions, but this requires implementing and maintaining the
models in said specialist software packages. Other types of
mathematical models may require solving an optimisation
problem (Boukouvala et al., 2016). For model discrimina-
tion, we wish to be agnostic with regards to the software
implementation or model type, since this flexibly (i) allows
faster model prototyping and development, and (ii) satisfies
the personal preferences of researchers and engineers.
2.2. Bayesian Design of Experiments
Methods for accommodating non-analytical model functions
have developed in parallel with increasing computer speed.
These methods are typically closer to fully Bayesian than the
classical analytical methods. Vanlier et al. (2014) approx-
imate the marginal predictive distributions of M models
and their Jensen-Shannon divergence using Markov chain
Monte Carlo (MCMC) sampling and a k-nearest neighbours
density estimate. On the downside, the density estimates
become less accurate as the number of experimental obser-
vations increases (Vanlier et al., 2014) and the method is
computationally intensive (Ryan et al., 2016).
Instead of studying design of experiments for model discrim-
ination, statisticians have focused on design of experiments
and model discrimination separately (Chaloner & Verdinelli,
1995). Design of experiments can also be used to aid model
parameter estimation. They solve problems of the type
x∗ = arg max
x
Eθ,yN+1
[
U(yN+1,x,θ)
]
(2)
where the utility function U(·, ·, ·) serves to either discrim-
inate models or estimate parameters. Criteria for model
discrimination are handled separately, usually under the
name of model selection or hypothesis testing.
Ryan et al. (2015) use a Laplace approximation of the pos-
terior distribution p(θ | Dexp) combined with importance
sampling. Drovandi et al. (2014) develop a method based
on sequential Monte Carlo (SMC) that is faster than us-
ing MCMC. Woods et al. (2017) use a Monte Carlo ap-
proximation Φ(x) = 1B
∑B
b U(yb,x,θb) with (yb,θb) ∼
p(yb,θb|x) on which they place a Gaussian process prior.
Limitations These methods agnostically accommodate
non-analytical models using a Monte Carlo-approach but
require exhaustive model sampling in the model parame-
ter space. On a case study with four models, each with ten
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model parameters, and two design variables, the Vanlier et al.
(2014) MCMC method requires six days of wall-clock time
to compute two sets of four marginal predictive distributions.
This cost is impractical for pharmacokinetic applications,
where a physical experiment takes ≈1–4 days. SMC meth-
ods can converge faster than MCMC methods (Woods et al.,
2017). But SMC methods can suffer from sample degener-
acy, where only a few particles receive the vast majority of
the probability weight (Li et al., 2014). Also, convergence
analysis for MCMC and SMC methods is difficult.
Furthermore, these methods are only for design of experi-
ments. Once an experiment is executed, the model discrim-
ination issue remains. In this case the marginal predictive
distributions p(f i |x,Dexp) would enable calculating the
model likelihoods.
3. Method
We wish to exploit results from the classical analytical ap-
proach to design of experiments for model discrimination,
while considering that we may deal with non-analytical
model functions. The key idea is replacing the original
(non-analytical) model functions with analytical and differ-
entiable surrogate models. The surrogate models can be
learnt from model evaluations. We choose to use GPs to
construct the surrogate models because they are flexible re-
gression tools that allow us to extract gradient information.
A GP is a collection of random variables, any finite sub-
set of which is jointly Gaussian distributed (Rasmussen
& Williams, 2006, p. 13) and fully specified by a mean
function m(·) and a kernel function k(·, ·). Prior knowl-
edge about the model functions f i can be incorporated
into the choice of m and k. To construct the GP surro-
gates, target data is needed. The purpose of the surro-
gate model is to predict the outcome of a model evaluation
fi(x,θi), rather than the outcome of a physical experiment
ftrue(x). Hence, for each modelMi we create a data set
Dsim,i = {f˜ `, x˜`, θ˜`; ` = 1, . . . , Nsim,i} of simulated ob-
servations, i.e. model evaluations f˜ ` = f i(x˜`, θ˜`), where
x˜` and θ˜` are sampled from X and Θi, respectively. Note
the difference between the experimental data set Dexp and
the simulated data sets Dsim,i: whereas the data set Dexp
has few (noisy, biological) observations, Dsim,i has many
(noise-free, artificial) observations.
We place independent GP priors fi,(e) ∼ GP(mi,(e), ki,(e))
on each target dimension e = 1, . . . , E of the model func-
tion f i, i = 1, . . . ,M . For notational simplicity, let
f = fi,(e), m = mi,(e), k = ki,(e) and z> = [x>,θ
>
i ].
Given Dsim,i with model evaluations [f˜ ]` = f˜` at loca-
tions [Z˜]` = z˜` the predictive distribution p(f |z∗, f˜ , Z˜) =
N (µ(z∗), σ2(z∗) at a test point z∗ is given by
µ(z∗) = m(z∗) + k>∗K
−1(f˜ −m) , (3)
σ2(z∗) = k(z∗, z∗)− k>∗K−1k∗ , (4)
where the covariance vector is [k∗]` = k(z˜`, z∗), the kernel
matrix is [K]`1,`2 = k(z˜`1 , z˜`2) + σ
2
nδ`1,`2 , and the target
mean is [m]` = m(z˜`), with a small artificial noise variance
σ2n  1 added for numerical stability. Note the simplified
notation µ = µi,(e) and σ2 = σ2i,(e).
Pharmacokinetic models are often formulated as systems of
ordinary differential equations, e.g. Han et al. (2006), where
the solutions are smooth functions. If we wish to model
these functions with a GP, it makes sense to use a covariance
function that encodes the smoothness of the underlying func-
tion, e.g. the radial basis function (RBF) covariance function
kRBF(z, z
′) = ρ exp
(− 12 (z − z′)>Λ−1(z − z′)), since
it corresponds to Bayesian linear regression with an infinite
number of basis functions (Rasmussen & Williams, 2006).
Our method extends to other choices of covariance function.
Each function sample f drawn from a zero-mean GP is
a linear combination f(x) =
∑
j ωjk(x,xj) of covari-
ance function terms (Rasmussen & Williams, 2006, p. 17).
Different model characteristics, e.g. smoothness or peri-
odicity, make alternate covariance functions appropriate.
The RBF covariance function is common, but its strong
smoothness prior may be too unrealistic for some systems.
Other choices include: Mate´rn, polynomial, periodic, and
non-stationary covariance functions. Sums or products of
valid covariance functions are still valid covariance func-
tions. Covariance functions can also model different be-
haviour over different input regions (Ambrogioni & Maris,
2016). Choosing the covariance function requires some
prior knowledge about the modelled function characteris-
tics, e.g. a periodic covariance function may be appropriate
to model periodic drug dosing.
In kRBF, and other similar covariance functions, ρ2 is the
signal variance and Λ = diag(λ21:D′) is a diagonal matrix
of squared length scales, with z ∈ RD′ . Together, ρ, Λ and
the artificial noise variance σ2n (inK) are the GP hyperpa-
rameters. Because the data set Dsim,i is arbitrarily large, we
use point-estimate hyperparameters learnt through standard
evidence maximisation.
We study a single model function f = f i and its
GP surrogates. Using the GP surrogates we can pre-
dict the outcome of a model evaluation f(x,θ) ∼
p(f | z,Dsim,i) = N (µ(z),Σ(z)), where µ = [µ(1:E)]>
and Σ = diag(σ2(1:E)). We approximate the (marginal) pre-
dictive distribution p(f |x,Dsim,i,Dexp) to account for the
model parameter uncertainty θ ∼ p(θ | Dexp) due to param-
eter estimation from the noisy experimental data Dexp.
3.1. Model Parameter Marginalisation
We assume that the experimental observations y1:N ∈ Dexp
have i.i.d. zero-mean Gaussian distributed measurement
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noise with known covariance Σexp. Let ∇θg denote the
gradient ∂g(x,θ)/∂θ|θ=θˆ of a function g with respect to
the model parameter θ, evaluated at θ = θˆ, and∇2θg denote
the corresponding Hessian.
We approximate the model parameter posterior distribution
p(θ | Dexp) ≈ N (θˆ,Σθ) as a Gaussian distribution around
the best-fit model parameter values θˆ. Using the same first-
order approximation as the classical analytical method in
(1), with Ef [f |x,θ] = µ(x,θ), yields
Σ−1θ =
N∑
n=1
∇θµn>Σ−1exp∇θµn ,
where µn = µ(xn,θ), with xn ∈ Dexp. We approximate
the marginal predictive distribution p(f |x,Dsim,Dexp) ≈
N (µ˘(x), Σ˘(x)) using a first- or second-order Taylor expan-
sion around θ = θˆ, where
µ˘(x) = Eθ[µ |x,θ] (5)
Σ˘(x) = Eθ[Σ |x,θ] + Vθ[µ |x,θ] , (6)
which we will detail in the following.
First-order Taylor approximation assumes that the
model function f is (approximately) linear in the model
parameters in some neighbourhood around θ = θˆ
µ(e)(x,θ) ≈ µ(e)(x, θˆ) +∇θµ(e)(θ − θˆ) , (7)
σ2(e)(x,θ) ≈ σ2(e)(x, θˆ) +∇θσ2(e)(θ − θˆ) . (8)
Inserting (7) into (5) yields the approximate mean of the
marginal predictive distribution
µ˘(x) ≈ µ(x, θˆ) . (9)
Similarly, inserting (8) into (6), the approximate expectation
of the variance becomes
Eθ[Σ |x,θ] ≈ Σ(x, θˆ) , (10)
and the variance of the mean becomes
Vθ[µ |x,θ] ≈ ∇θµΣθ∇θµ> . (11)
(9)–(11) yield a tractable first-order Taylor approximation
to p(f |x,Dsim,Dexp) = N (µ˘(x), Σ˘(x)).
Second-order Taylor expansion assumes that the model
function f is (approximately) quadratic in the model param-
eters in some neighbourhood around θ = θˆ
µ(e)(x,θ) ≈ µ(e)(x, θˆ) +∇θµ(e)(θ − θˆ)
+ 12 (θ − θˆ)>∇2θµ(e)(θ − θˆ) ,
(12)
σ2(e)(x,θ) ≈ σ2(e)(x, θˆ) +∇θσ2(e)(θ − θˆ)
+ 12 (θ − θˆ)>∇2θσ2(e)(θ − θˆ) .
(13)
Inserting (12) into (5) yields the approximate mean of the
marginal predictive distribution
µ˘(e)(x) ≈ µ(e)(x, θˆ) + 12 tr
(∇2θµ(e)Σθ) . (14)
Similarly, inserting (13) into (6) yields the diagonal approx-
imate expectation of the variance with elements
Eθ[σ2(e) |x,θ] ≈ σ2(e)(x, θˆ) + 12 tr
(
∇2θσ2(e)Σθ
)
. (15)
The variance of the mean is a dense matrix with elements
Vθ[µ(e1), µ(e2) |x,θ] ≈ ∇θµ(e1)Σθ∇θµ>(e2)
+
1
2
tr
(∇2θµ(e1)Σθ∇2θµ(e2)Σθ) . (16)
(14)–(16) yield a tractable second-order Taylor approxima-
tion to p(f |x,Dsim,Dexp) = N (µ˘(x), Σ˘(x)).
Figure 2 illustrates the process of constructing the GP sur-
rogate models and the approximations of the marginal pre-
dictive distributions. Firstly, the model parameters are es-
timated from Dexp. Secondly, Dsim is created from model
evaluations and used (i) to learn the GP surrogate’s hy-
perparameters, and (ii) as target data for GP predictions.
Thirdly, the approximationN (µ˘(x), Σ˘(x)) of the marginal
predictive distribution is computed. Fourthly and lastly, the
marginal predictive distribution is used to design the next
experiment and approximate the model likelihood.
4. Results
The following demonstrates that our approach for model
discrimination with GP surrogate models exhibits a similar
performance to the classical analytical method, but can be
used to design experiments to discriminate between non-
analytical model functions. The GP surrogate method per-
formance will be studied using two different case studies.
Case study 1 has analytical model functions, so we can
compare how well our new method performs compared to
the classical analytical methods in Section 2.1. Case study
2 has pharmacokinetic-like models consisting of systems of
ordinary differential equations.
In both case studies we compute the following metrics:
(A) the average number of additional experiments N −N0
required for all incorrect models to be discarded.
(SE) the standard error of the average (A).
(S) success rate; the proportion of tests in which all incor-
rect models were discarded.
(F) failure rate; the proportion of tests in which the correct
(data-generating) model was discarded.
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(a) Experimental data Dexp and model prediction f(x, θˆ) (b) Simulated data Dsim, and prediction N (µ(x, θˆ),Σ(x, θˆ))
(c) Prediction N (µ˘(x), Σ˘(x)) (d) Dexp and prediction N (µ˘(x), Σ˘(x) +Σexp).
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Figure 2. Process of constructing the approximation of the marginal predictive distribution to design a new experiment and perform
model discrimination. (a) Step 1, use experimental data Dexp to perform model parameter estimation and find θˆ. (b) Step 2, generate
simulated data Dsim by sampling from the model f . Use Dsim to learn hyperparameters of the GP surrogate model. (c) Step 3, use Taylor
approximation to compute µ˘ and Σ˘. Use approximation of marginal predictive distribution to design a new experiment. (d) Step 4, use
the approximation of the predictive distribution to compute the model likelihood and perform model discrimination.
(I) the proportion of inconclusive tests (all models were
deemed inaccurate or the maximum number of addi-
tional experiments Nmax −N0 was reached).
We compare the design criteria (DC) DBH, DBF and DAW
described in Section 2.1 as well as random uniform sampling
(denoted Uni.). We also compare the three different criteria
for model discrimination (MD) described in Section 2.1:
updated posterior likelihood piN,i, the χ2 adequacy test, and
the Akaike information criterion (AIC).
4.1. Case Study 1: Comparison to Analytical Method
Case study 1 is from the seminal paper by Buzzi-Ferraris
et al. (1984). With two measured states y1, y2 and two
design variables x1, x2 ∈ [5, 55], we discriminate between
four chemical kinetic models Mi, each with four model
parameters θi,j that we fix to θi,j ∈ [0, 1]:
M1 : f(1) = θ1,1x1x2/g1 , f(2) = θ1,2x1x2/g1 ,
M2 : f(1) = θ2,1x1x2/g22 , f(2) = θ2,2x1x2/h22,1 ,
M3 : f(1) = θ3,1x1x2/h23,1 , f(2) = θ3,2x1x2/h23,2 ,
M4 : f(1) = θ4,1x1x2/g4 , f(2) = θ4,2x1x2/h4,1 ,
where gi = 1 + θi,3x1 + θi,4x2 and hi,j = 1 + θi,2+jxj .
Buzzi-Ferraris et al. (1984) generate the experimental data
Dexp from model M1 using θ1,1 = θ1,3 = 0.1 and
θ1,2 = θ1,4 = 0.01 and Gaussian noise covariance Σexp =
diag(0.35, 2.3e-3). We start each test with N0 = 5 ran-
domly sampled experimental observations, and set a maxi-
mum budget of Nmax −N0 = 40 additional experiments.
Tables 1–3 compare the performance in 500 completed test
instances of the classical analytical approach to the GP
surrogate method using first- or second-order Taylor ap-
proximations. For this case study, the GP surrogate method
performs similarly to the classical analytical approach. We
see that the average number of required additional experi-
ments (A) increases using pi for model discrimination, but
that the model discrimination success rate (S) also increases.
The model discrimination failure rate drops for almost all
MD/DC combinations using the GP surrogate method. We
also see that even for this simple case study, the difference
in performance between the design criteria and random sam-
pling is significant. The low average (A) for pi/Uni. in
Table 1 is likely an artefact due to the large failure rate (F).
4.2. Case Study 2: Non-Analytical Models
Case study 2 is from Vanlier et al. (2014). There are four dif-
ferent models, described by ordinary differential equations.
The supplementary material contains the full model descrip-
tions. The models describe a biochemical network, and are
similar to typical pharmacokinetic models in (i) the use of
reversible reactions, and (ii) the number of parameters and
equations (see e.g. Han et al. (2006)).
We assume two measured states (E = 2), with model pa-
rameters θi ∈ [0, 1]10, initial concentrations c ∈ [0, 1]E ,
measurement time point t ∈ [0, 20], and design variables
x> = [t, c>]. We follow Vanlier et al. (2014) and letM1
generate the observed experimental data, with random uni-
formly sampled true model parameters and experimental
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Figure 3. Results from case study 2 with 4 models using the DAW design criterion and AIC for model discrimination. (a)–(d) show the
evolution of the Akaike weights wi for modelM1, . . . ,M4, respectively, for 63 completed tests. (e) shows the average Akaike weight
evolutions (with one standard deviation) in (a)–(d). The results indicate that modelsM1 andM2 are indiscriminable.
measurement noise covariance Σexp = 9.0× 10−4I . Each
test is initiated with N0 = 20 observations at random de-
sign locations x1, . . . ,xN0 . We set a maximum budget of
Nmax −N0 = 100 additional experiments.
Case study 1 shows no obvious benefit in using the second-
order over a first-order Taylor approximation. Hence, in
case study 2 we only performance test the GP surrogate
method with the first-order Taylor approximation.
Table 1. Results from case study 1 using the analytical approach.
MD pi χ2 AIC pi χ2
DC DBH DBF DAW Uni. Uni.
A 2.60 2.87 2.08 3.43 10.39
SE 0.04 0.12 0.04 0.11 0.45
S [%] 86.4 64.2 62.4 59.0 85.8
F [%] 13.6 5.0 37.6 40.6 4.4
I [%] 0.0 30.8 0.0 0.4 9.8
Table 2. Results from case study 1 using the GP surrogate method
with first-order Taylor approximation.
MD pi χ2 AIC pi χ2
DC DBH DBF DAW Uni. Uni.
A 4.31 2.23 2.72 10.99 10.02
SE 0.09 0.06 0.08 0.34 0.45
S [%] 95.6 47.4 88.6 69.6 83.6
F [%] 4.4 4.8 11.4 30.4 4.8
I [%] 0.0 47.8 0.0 0.0 11.6
Table 3. Results from case study 1 using the GP surrogate method
with second-order Taylor approximation.
MD pi χ2 AIC pi χ2
DC DBH DBF DAW Uni. Uni.
A 4.14 2.29 2.64 9.53 10.11
SE 0.09 0.07 0.06 0.30 0.47
S [%] 96.9 46.6 90.1 64.3 80.2
F [%] 3.1 9.9 9.9 35.7 7.0
I [%] 0.0 43.5 0.0 0.0 12.8
The results in Table 4 for 4 models show that the rates of
inconclusive results are higher for case study 2 than for
case study 1. Furthermore, the ratio of successful model
discriminations to failed model discriminations are lower
for pi/DBH and AIC/DAW than they are in case study 1.
This is because for case study 2 the experimental noise is
often larger than the difference between the model predic-
tions. Figure 3 shows the evolutions of the Akaike weights
wi (Michalik et al., 2010) for all 63 completed tests. The
Akaike weight evolutions show that especially modelsM1
andM2 are difficult to discriminate between, given that we
only consider two measured states. Corresponding graphs
for pi and χ2 are similar-looking. One can also see from the
model formulations (see supplementary material) that all
models are similar.
To verify that the Table 4 results for 4 models are indeed due
to the indiscriminability of modelM1 andM2, we carry
out another set of tests where we only consider modelsM1,
M3 andM4. The results in Table 4 for 3 models show that
removing modelM2 enables the GP surrogate method to
correctly discriminate between the remaining models more
successfully. In practice, researchers faced with apparent
model indiscriminability have to rethink their experimental
set-up to lower measurement noise or add measured states.
Table 4. Results from case study 2.
4 models 3 models
MD pi χ2 AIC pi χ2 AIC
DC DBH DBF DAW DBH DBF DAW
A 20.10 39.83 29.62 15.80 21.91 9.74
SE 3.72 12.09 7.72 2.05 2.52 1.70
S [%] 15.9 9.5 33.3 89.5 77.2 95.6
F [%] 7.9 0.0 7.9 6.1 0.9 1.8
I [%] 76.2 90.5 58.7 4.4 21.9 2.6
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5. Discussion
The healthcare industry already uses machine learning to
help discover new drugs (Pfizer, 2016). But passing the pre-
clinical stage is expensive. DiMasi et al. (2016) estimate
the average pre-approval R&D cost to $2.56B (in 2013 U.S.
dollars) with a yearly increase of 8.5 %. For the pre-clinical
stage (before human testing starts), DiMasi et al. (2016)
estimate the R&D cost to $1.1B.
Model discrimination, which takes place in the pre-clinical
stage, may lower drug development cost by identifying a
model structure quickly. Heller et al. (2018) explain that a
major hurdle for in silico pharmacokinetics is the difficulty
of model discrimination. Scannell & Bosley (2016) and
Plenge (2016) also attribute a significant part of the total
R&D cost for new drugs to inaccurate models passing the
pre-clinical stage only to be discarded in later clinical stages.
Inaccurate models need to be discarded sooner rather than
later to avoid expensive failures.
Design of experiments for model discrimination has typi-
cally focussed either on analytical approaches, which cannot
manage all functions, or on data-driven approaches, which
may have computational difficulties or lack interpretable
marginal predictive distributions. We leverage advantages
of both approaches by hybridising the analytical and data-
driven approaches, i.e. we replace the analytical functions
from the classical methods with GP surrogates.
The novel GP surrogate method is highly effective. Case
study 1 directly compares it with the analytical approach on
a classical test instance. The similar performance indicates
successful hybridisation between analytical and data-driven
approaches. Case study 2 considers an industrially relevant
problem suffering from model indiscriminability. The GP
surrogate method successfully avoids introducing overconfi-
dence into the model discrimination despite the assumptions
used to derive the marginal predictive distribution.
The parameter estimation step is limited to few and noisy
data points, e.g. from time-consuming pharmacokinetic ex-
periments. If the approximation p(θ | Dexp) ≈ N (θˆ,Σθ)
is not accurate, the Section 3.1 Taylor approximations of µ˘
and Σ˘ can be extended to a mixture of Gaussian distribu-
tions p(θ | Dexp) =
∑
j ωjN (θˆj ,Σθ,j), with
∑
j ωj = 1,
if {θˆj ,Σθ,j} are given. The analytical approximations sac-
rifice some accuracy for computational tractability: Our
computational time for design of experiments in case study
2 was on the order of minutes, whereas the method of Van-
lier et al. (2014) requires days. Our results indicate that the
approximations work well in practice. GP surrogate meth-
ods could sharply reduce the cost of drug development’s pre-
clinical stage, e.g. by shrinking the time needed to decide
on a new experiment or by finding a good model structure
in a reduced number of pharmacokinetic experiments.
Our new method directly applies to neighbouring fields. For
example, dual control theory deals with control of unknown
systems, where the goal is to balance controlling the system
optimally vs. learning more about the system. When rival
models predict the unknown system behaviour, learning
about the system involves designing new experiments, i.e.
control inputs to the system (Cheong & Manchester, 2014).
This design of experiments problem, e.g. in Larsson et al.
(2013), would be likely to have very strict time requirements
and benefit from confidence bounds on the model predic-
tions. Our method also applies to neighbouring application
areas, e.g. distinguishing between microalgae metabolism
models (Ulmasov et al., 2016) or models of bone neotissue
growth (Mehrian et al., 2018).
A very hot topic in machine learning research is learn-
ing in implicit generative models (Mohamed & Laksh-
minarayanan, 2017), e.g. generative adversarial networks
(GANs) (Goodfellow et al., 2014), which employ a form
of model discrimination. Here the likelihood function
p(y |Mi) is not given explicitly, so the goal is to learn
an approximation q(y |Mi) of the data distribution p(y).
The model discrimination tries to identify from which distri-
bution q(y |Mi) or p(y) a random sample has been drawn.
For the case of design of experiments for model discrim-
ination, we have a prescribed probabilistic model, since
we explicitly specify an approximation of the likelihood
p(y |Mi,x,θi). But we have (i) the physical experiments,
the true but noisy data generator that is expensive to sam-
ple, and (ii) the rival models, deterministic and relatively
cheap (but probably inaccurate!) data generators. Design
of experiments for model discrimination also ties in with
several other well-known problems in machine learning, e.g.
density estimation, distribution divergence estimation, and
model likelihood estimation.
6. Conclusions
We have presented a novel method of performing design
of experiments for model discrimination. The method hy-
bridises analytical and data-driven methods in order to ex-
ploit classical results while remaining agnostic to the model
contents. Our method of approximating the marginal pre-
dictive distribution performs similarly to classical meth-
ods in a case study with simple analytical models. For an
industrially-relevant system of ordinary differential equa-
tions, we show that our method both successfully discrimi-
nates models and avoids overconfidence in the face of model
indiscriminability. The trade-off between computational
complexity and accuracy that we introduce is useful for
design of experiments for discrimination e.g. between phar-
macokinetic models, where the duration of the experiments
is shorter than or one the same time-scale as the computa-
tional time for Monte Carlo-based methods.
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A. Table of Notation
Table A. Summary of notation.
Symbol Description
f i Function associated with modelMi
fi,(e) Dimension e of function f i; e = 1, . . . , E
x Design variable, x ∈ X ⊂ Rd
θi Parameters of modelMi , θi ∈ Θi ⊂ RDi
M No. of modelsMi; i = 1, . . . ,M
E No. of target dimensions; f i : Rd+Di → RE
Σexp Measurement noise covariance
Dexp The set of experimental observations
Dsim,i The set of simulated data for modelMi
B. Design Criteria
We let ∆ij = f i(x, θˆi) − f j(x, θˆj) and the covariance
Σi = Σexp + Σ˘i(x), where Σ˘i(x) is the covariance of
modelMi’s marginal predictive distribution due to model
parameter uncertainty.
For a single-response system, Box & Hill (1967) derive the
design criterion DBH, later generalised to a multi-response
form by Prasad & Someswara Rao (1977)
DBH(x) =
M∑
i,j=1
piN,ipiN,j
2
{
∆>ij
(
Σ−1i +Σ
−1
j
)
∆ij
+ tr
(
ΣiΣ
−1
j +ΣjΣ
−1
i − 2I
)}
.
Buzzi-Ferraris et al. (1990) derive the design criterion DBF
DBF(x) = max
1≤i,j≤M
{
∆>ij (Σi +Σj)
−1
∆ij
+ tr
(
2Σexp (Σi +Σj)
−1
)}
.
designed such that if maxxDBF(x) < E, the largest differ-
ence between model predictions is too small compared to
the measurement noise variance to carry out model discrim-
ination, and design of experiments terminates.
Michalik et al. (2010) proceed from the Akaike informa-
tion criterion (AIC) as the model discrimination criterion to
derive a design criterion DAW from the Akaike weights
wi(x) =
1∑M
j=1 exp
(−1
2 ∆
>
ijΣ
−1
i ∆ij +Di −Dj
) ,
yielding DAW =
∑
i wip(Mi), where p(Mi) is the prior
probability of modelMi.
C. Case study from Vanlier et al. (2014)
There are nine chemical components with concentrationsCi,
i = 1, . . . , 9. The system of ordinary differential equations
has the form
dC1/dt = −g1 + g2 ,
dC2/dt = g1 − g2 ,
dC3/dt = −g3 + g4 ,
dC4/dt = g3 − g4 − g5 + g6 ,
dC5/dt = −g9 + g10 ,
dC6/dt = −g5 + g6 + g9 − g10 ,
dC7/dt = g5 − g6 ,
dC8/dt = −g7 + g8 ,
dC9/dt = g7 − g8 ,
i.e. the stoichiometry is the same for all modelsMi. But
some of the fluxes g1, . . . , g10 differ for the different models.
For all modelsMi the following fluxes are identical:
g2 = θi,2C2 , g7 = θi,7C8 ,
g4 = θi,4C4 , g8 = θi,8C9 ,
g5 = θi,5C4C6 , g9 = θi,10C5 ,
g6 = θi,6C7 , g10 = θi,4C6 .
For flux g1 the models differ in the following way:
Mi : g1 = θi,1C1 , i ∈ {1, 3, 4}
M2 : g1 = θ2,1C1
θ2,9 + C7
.
For flux g3 the models differ in the following way:
M1 : g3 = θ1,3C2C3θ1,9+C7 , M3 : g3 =
θ3,3C2C3
θ3,9+C9
,
M2 : g3 = θ2,3C2C3 , M4 : g3 = θ4,3C2C3θ4,9+C8 .
We assume that the only measured states are the concentra-
tions C4 and C9, because these are the states from which
Vanlier et al. (2014) collect their initial data. Similarly, we
use the initial concentrations C4(t = 0) and C9(t = 0) as
two of our design variables, the third design variable being
the time point t at which to measure the concentrations.
Vanlier et al. (2014) look at times points in the range
t ∈ [0, 20], which we also adopt. We assume the initial
concentrations C4(t = 0), C9(t = 0) ∈ [0, 1] and fix all
other initial concentrations to
C1(t = 0) = C3(t = 0) = C5(t = 0) = C8(t = 0) = 1 ,
C2(t = 0) = C6(t = 0) = C7(t = 0) = 0.1 .
We assume the model parameter space θ ∈ [0, 1]10. Simula-
tions show that sampling from this parameter space gives a
wide range of model realisations.
With reference to modelsM1 andM2 being similar, we
see that the only difference between them is that the term
θi,9 + C7 divides g1 and g3 forM1 andM2, respectively.
If C7 is small compared to θi,9, then the models are nearly
identical.
